Epizyme (EPZM) : Traders are bullish on Epizyme (EPZM) as it has outperformed the S&P 500 by a wide margin of 16.08% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 27.67%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 28.35% in the last 1 week, and is up 13.73% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 18.8% and the 50-Day Moving Average is 3.71%.The 200 Day SMA reached 13.81% Epizyme, Inc. has dropped 18.88% during the last 3-month period . Year-to-Date the stock performance stands at -42.07%.
Epizyme (EPZM) : 6 investment research analysts covering Epizyme (EPZM) have an average price target of $25.17 for the near short term. The highest target price given by the Brokerage Firm to the stock is $39 and the lowest target is $18 for the short term. Analysts expect the variance to be within $7.36 of the average price.
For the current week, the company shares have a recommendation consensus of Buy. Epizyme (NASDAQ:EPZM): The stock opened at $8.9 and touched an intraday high of $9.39 on Friday. During the day, the stock corrected to an intraday low of $8.87, however, the bulls stepped in and pushed the price higher to close in the green at $9.28 with a gain of 4.39% for the day. The total traded volume for the day was 1,192,007. The stock had closed at $9.28 in the previous trading session.
Epizyme, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Companys product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. The Companys lead product candidate, EPZ-6438 is an inhibitor that targets the EZH2 HMT. The Company is conducting a Phase I/II clinical trial of EPZ-6438 in patients with relapsed or refractory B-cell lymphoma or advanced solid tumors. Its product pipeline includes EPZ-6438 (EZH2 inhibitor) and EPZ-5676 (DOT1L inhibitor). It has commercial rights for EPZ-6438 (EZH2 inhibitor) under the name Epizyme across the world excluding Japan and as Eisai in Japan. EPZ-5676 (DOT1L inhibitor) is in Phase I MLL-r adult patient trial ongoing for dose escalation fully enrolled in MLL-r adult patient trial and MLL-r only adult expansion enrolling, and Phase I MLL-r pediatric patient trial enrolling.